Fundraising Fox
/Companies
Sign in

Galecto Biotech

10 known investors

Find your way into Galecto Biotech

762 people in our graph can introduce you to the Galecto Biotech team.

Sign up to see every warm intro you have to Galecto Biotech

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Galecto Biotech team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. Its lead asset, DMR-001, is an investigational monoclonal antibody targeting mutCALR, with a first regulatory submission planned for mid-2026.

BiotechMedical Devices

Founders & leadership

JJJennifer Jarrett
Jennifer JarrettChief Executive Officer & Board DirectorChief Executive Officer & Board Director at Damoratx
SSSherwin Sattarzadeh
Sherwin SattarzadehChief Operating OfficerSherwin Sattarzadeh is Chief Operating Officer at Galecto Biotech, a biotechnology company developing targeted treatments for myeloproliferative neoplasms. He brings over 20 years of experience in biotechnology and pharmaceutical development across multiple therapeutic areas, with background in clinical development strategy and operational leadership.
BHBecker Hewes
Becker HewesChief Medical Officer
GWGarrett Winslow
Garrett WinslowGeneral CounselGarrett Winslow is General Counsel at Galecto Biotech and brings experience in biopharma legal matters across law firms and in-house roles, with expertise in securities, corporate governance, and intellectual property.
JBJim Baker
Jim BakerChief Corporate Affairs OfficerJim Baker has over 20 years of experience in biotech corporate affairs and operations, including nearly a decade at Blueprint Medicines where he helped build corporate affairs infrastructure as the company scaled to commercialize marketed medicines, and prior roles at Biogen, Sarepta Therapeutics, PTC Therapeutics, and Idera Pharmaceuticals. He holds B.A. degrees in journalism and political science from the University of Southern California and served as a Captain in the U.S. Army Signal Corps.
BBBrian Burkavage
Brian BurkavageSenior Vice President, Finance
HS
Hans SchambyeFounder

Investors · 10

Hadean Ventureslisted by Hadean VenturesOslo

How we know: Hadean Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

M Ventureslisted by M VenturesAmsterdam · $10.8M

How we know: M Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

SEED Capital Denmarklisted by SEED Capital DenmarkCopenhagen · $2M – $4M

How we know: SEED Capital Denmark's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Seventure Partnerslisted by Seventure PartnersParis

How we know: Seventure Partners's portfolio page · Not right? Tell us

Sunstone Capitallisted by Sunstone CapitalFrederiksberg

How we know: Sunstone Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Ysios Capitallisted by Ysios CapitalBarcelona · $5.4M – $21.6M

How we know: Ysios Capital's portfolio page · funding news · the VCSheet dataset · Not right? Tell us

Maverick VenturesreportedSan Francisco · $3M – $10M

How we know: the VCSheet dataset · Not right? Tell us

Novo HoldingsreportedCopenhagen · $1.1M – $54M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

OrbiMedreportedNew York · $1M – $75M

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries COct 2018 · 2 sources
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does Galecto Biotech do?
Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. Its lead asset, DMR-001, is an investigational monoclonal antibody targeting mutCALR, with a first regulatory submission planned for mid-2026.
Who are Galecto Biotech's investors?
Galecto Biotech's investors include EIR Ventures, Hadean Ventures, M Ventures, SEED Capital Denmark, Seventure Partners, Sunstone Capital, Ysios Capital, Maverick Ventures and 2 more.